Literature DB >> 21963870

Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

Kae Pusic1, Hengyi Xu, Andrew Stridiron, Zoraida Aguilar, Andrew Wang, George Hui.   

Abstract

In this proof-of-concept study we report the use of <15 nm, water soluble, inorganic nanoparticles as a vaccine delivery system for a blood stage malaria vaccine. The recombinant malarial antigen, Merozoite Surface Protein 1 (rMSP1) of Plasmodium falciparum served as the model vaccine. The rMSP1 was covalently conjugated to polymer-coated quantum dot CdSe/ZnS nanoparticles (QDs) via surface carboxyl groups, forming rMSP1-QDs. Anti-MSP1 antibody responses induced by rMSP1-QDs were found to have 2-3 log higher titers than those obtained with rMSP1 administered with the conventional adjuvants, Montanide ISA51 and CFA. Moreover, the immune responsiveness and the induction of parasite inhibitory antibodies were significantly superior in mice injected with rMSP1-QDs. The rMSP1-QDs delivered via intra-peritoneal (i.p.), intra-muscular (i.m.), and subcutaneous (s.c.) routes were equally efficacious. The high level of immunogenicity exhibited by the rMSP1-QDs was achieved without further addition of other adjuvant components. Bone marrow derived dendritic cells were shown to efficiently take up the nanoparticles leading to their activation and the expression/secretion of key cytokines, suggesting that this may be a mode of action for the enhanced immunogenicity. This study provides promising results for the use of water soluble, inorganic nanoparticles (<15 nm) as potent vehicles/platforms to enhance the immunogenicity of polypeptide antigens in adjuvant-free immunizations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963870      PMCID: PMC3202662          DOI: 10.1016/j.vaccine.2011.09.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  55 in total

Review 1.  Chitosan for mucosal vaccination.

Authors:  I M van der Lubben; J C Verhoef; G Borchard; H E Junginger
Journal:  Adv Drug Deliv Rev       Date:  2001-11-05       Impact factor: 15.470

Review 2.  Microparticles as vaccine adjuvants and delivery systems.

Authors:  Derek T O'Hagan; Manmohan Singh
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

3.  Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli.

Authors:  W H Leung; Z Q Meng; G Hui; W K K Ho
Journal:  Biochim Biophys Acta       Date:  2004-11-18

Review 4.  The immunoepidemiology of human hookworm infection.

Authors:  R J Quinnell; J Bethony; D I Pritchard
Journal:  Parasite Immunol       Date:  2004 Nov-Dec       Impact factor: 2.280

5.  A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.

Authors:  S P Chang; H L Gibson; C T Lee-Ng; P J Barr; G S Hui
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

6.  Drug-incorporating calcium carbonate nanoparticles for a new delivery system.

Authors:  Y Ueno; H Futagawa; Y Takagi; A Ueno; Y Mizushima
Journal:  J Control Release       Date:  2004-12-15       Impact factor: 9.776

7.  Antigen-presenting dendritic cells rescue CD4-depleted CCR2-/- mice from lethal Histoplasma capsulatum infection.

Authors:  Wendy A Szymczak; George S Deepe
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

8.  Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives.

Authors:  Takami Akagi; Xin Wang; Tomofumi Uto; Masanori Baba; Mitsuru Akashi
Journal:  Biomaterials       Date:  2007-04-20       Impact factor: 12.479

9.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Authors:  S P Chang; S E Case; W L Gosnell; A Hashimoto; K J Kramer; L Q Tam; C Q Hashiro; C M Nikaido; H L Gibson; C T Lee-Ng; P J Barr; B T Yokota; G S Hut
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

Review 10.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

View more
  5 in total

1.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

2.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

3.  Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.

Authors:  Kae Pusic; Zoraida Aguilar; Jaclyn McLoughlin; Sophie Kobuch; Hong Xu; Mazie Tsang; Andrew Wang; George Hui
Journal:  FASEB J       Date:  2012-11-29       Impact factor: 5.191

Review 4.  The Use of Synthetic Carriers in Malaria Vaccine Design.

Authors:  Liam Powles; Sue D Xiang; Cordelia Selomulya; Magdalena Plebanski
Journal:  Vaccines (Basel)       Date:  2015-10-29

Review 5.  Recent advances in recombinant protein-based malaria vaccines.

Authors:  Simon J Draper; Evelina Angov; Toshihiro Horii; Louis H Miller; Prakash Srinivasan; Michael Theisen; Sumi Biswas
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.